JBCHEPHARM (JBCHEPHARM) is currently trading at N/A per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

J.B. Chemicals & Pharmaceuticals Limited is a leading pharmaceutical company established in 1976, heavily engaged in the manufacture and marketing of diverse pharmaceutical formulations, herbal remedies, and APIs. The company continues to be one of the fastest growing organizations in the Indian pharmaceutical market, demonstrating superior performance with notable growth in key brands such as Cilacar, Sporlac, and Razel. J.B. Chemicals recently expanded through strategic acquisitions, including the Azmarda brand from Novartis, which fortifies its presence in the cardiology market. The company places a strong focus on expanding its domestic and international presence with a robust order book, driving both revenue and profit growth significantly above the industry average.

Over the past 52 weeks, JBCHEPHARM has traded between a low of ₹0.00 and a high of ₹0.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

JBCHEPHARM has a market capitalization of approximately N/A. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

JBCHEPHARM’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of N/A and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of N/A Cr, JBCHEPHARM is classified as a N/A stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

JBCHEPHARM operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of JBCHEPHARM is N/A. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

The NCLT sanctioned the scheme of amalgamation under Sections 230 to 232 of the Companies Act, allowing J.B. Chemicals to merge into Torrent Pharmaceuticals.

Eligible JB Pharma shareholders (excluding Torrent Pharma) will receive 51 equity shares of Torrent Pharma for every 100 JB Pharma shares they hold.

The board approved an interim dividend of ₹12.70 per equity share (face value ₹1) for FY2025-26.

The provided text cites consolidated Q4 FY25 revenue of about ₹949.5 crore and net profit (PAT) of about ₹146 crore, up roughly 10% and 15%-16% year-on-year, respectively.